In Vitro Toxicology
Our in vitro toxicity testing services provide reliable, human-relevant safety assessment using validated alternative methods. These assays are designed to support regulatory requirements while promoting ethical testing practices and reducing reliance on animal studies.
We offer scientifically robust in vitro approaches to assess skin and eye irritation assays, endocrine disruption assays, and phototoxicity and dermal absorption assays using internationally accepted OECD-aligned models. In addition to OECD test methods, we also provide in silico analysis to support safety assessment. These approaches enable accurate evaluation of local toxicity endpoints using reconstructed human tissue systems that closely reflect human biological responses.
Together, these in vitro assays support integrated testing strategies for food additives, agrochemicals, medical devices, industrial chemicals, and pharmaceuticals helping clients generate regulatory-ready safety data efficiently while aligning with global expectations for alternative testing and the 3R principles.
Key services include:
Exploratory studies (Non-GLP)
- Mini Ames
- Mini hERG (hERG screening)
- Dose range finding studies
- CVS function screening in telemetered dogs
OECD 431:
In vitro skin corrosion: Reconstructed Human Epidermis (RhE) test method
OECD 439:
In vitro skin irritation: RhE test methods
OECD 442C:
In vitro skin sensitisation assay- Direct Peptide Reactivity Assay (DPRA)
OECD 442D:
In vitro skin sensitisation assay-KeratinoSens assay
OECD 442E:
In vitro skin sensitisation assay- Human Cell Line Activation Test (hCLAT)
OECD 492:
In vitro eye irritation assay: Reconstructed Human Cornea-like Epithelium (RhCE) test
OECD 492B:
RhCE test method for eye hazard identification
OECD 437:
Bovine corneal opacity and permeability test method
OECD 455:
Estrogen Receptor Transactivation Assays (ERTA)
OECD 456:
H295R Steroidogenesis assay
OECD 458:
Androgen Receptor Transactivation Assays (ARTA)
OECD 493:
Human Recombinant Estrogen Receptor (hrER) - ER binding affinity (under validation)
Aromatase assay (under validation)
OECD TG432:
In vitro phototoxicity (Balb/c 3T3)
OECD 498:
In vitro phototoxicity - RhE phototoxicity test method
OECD 428:
In vitro dermal absorption (Franz cell) assay
- Organ-on-a-chip ( Microphysiological systems)
- Spheroids and organoids (under validation)
- Genomics solutions
Genomics Solutions For Oncology
Scientific Partnership
Partnering for Scientific Excellence
Adgyl Lifesciences is committed to ensure
Scientifically rigorous, reproducible and timely study execution.
High‑quality data generation aligned with scientific & regulatory requirements
Seamless end‑to‑end support spanning study design, execution, and data interpretation.
Connect with our expert team today to discuss how we can support your in vitro toxicology studies
what people ask
Frequently Asked Questions
Can you design a complete testing strategy for skin and eye safety?
Yes, we can recommend an integrated testing approach combining multiple assays (e.g., skin and eye irritation assays, endocrine disruption assays, and phototoxicity and dermal absorption assay) for comprehensive safety assessment.
What solutions do you offer for early-stage toxicity screening?
We provide rapid in vitro screening assays across organ toxicity screening (liver, kidney,) dermatological, ocular, phototoxic, and endocrine endpoints to support early decision-making.
Do you offer customised assay development for specific targets?
Yes, we can develop and optimise tailored assays/bioassays depending on your molecule, pathway, or biomarker of interest.
What capabilities do you have in immunology and cell-based testing?
We provide immune profiling (cytokines, TILs), checkpoint assays (PD-1/PD-L1), and functional immune assays to support immunology and oncology programs.
How do New Approach Methodologies (NAMs) benefit my research?
NAMs such as organ-on-chip, spheroids, organoids, and genomics platforms offer more predictive, human-relevant data while reducing reliance on animal testing.
